Sun Ming, Zhang Han
Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, 650031, China.
Heliyon. 2019 Mar 7;5(3):e01297. doi: 10.1016/j.heliyon.2019.e01297. eCollection 2019 Mar.
Mantle cell lymphoma (MCL) is a heterogeneous aggressive disease and remains incurable with current chemotherapies. The development of monoclonal antibody (mAb) has led to substantial achievement in immunotherapeutic strategies for B-cell lymphomas including MCL. Nonetheless, progress in the clinical use of mAbs is hindered by poor efficacy, off-target toxicities and drug resistance. Thus, novel mAbs engineering and approaches to improve target specificity and enhance affinity and potency are required. In this review, we highlight the latest advances of therapeutic antibodies in MCL, alone or in combination with other strategies and agents, with a particular focus on the current challenges and future prospective.
套细胞淋巴瘤（MCL）是一种异质性侵袭性疾病，目前的化疗方法仍无法治愈。单克隆抗体（mAb）的发展在包括MCL在内的B细胞淋巴瘤免疫治疗策略方面取得了重大成就。尽管如此，mAb在临床应用中的进展受到疗效不佳、脱靶毒性和耐药性的阻碍。因此，需要新型的mAb工程以及提高靶标特异性、增强亲和力和效力的方法。在本综述中，我们重点介绍了治疗性抗体在MCL中的最新进展，包括单独使用或与其他策略及药物联合使用的情况，特别关注当前面临的挑战和未来前景。
